Detection of familial hypercholesterolaemia: A major treatment gap in preventative cardiology

被引：36

作者：

Bates, Timothy R. ^{[1
,2
]}

Burnett, John R. ^{[1
,2
,3
,4
]}

van Bockxmeer, Frank M. ^{[4
,5
]}

Hamilton, Sandra ^{[1
,2
,6
]}

Arnolda, Leonard ^{[6
,7
]}

Watts, Gerald F. ^{[1
,2
,6
]}

机构：

[1] Royal Perth Hosp, Lipid Disorders Clin, Perth, WA 6847, Australia

[2] Royal Perth Hosp, Dept Internal Med, Perth, WA 6847, Australia

[3] Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Path W Lab Med WA, Perth, WA 6847, Australia

[4] Univ Western Australia, Sch Surg & Pathol, Perth, WA 6000, Australia

[5] Royal Perth Hosp, Path W Lab Med WA, Div Lab Med, Cardiovasc Genet Lab, Perth, WA 6847, Australia

[6] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6000, Australia

[7] Royal Perth Hosp, Dept Cardiol, Perth, WA 6847, Australia

来源：

HEART LUNG AND CIRCULATION | 2008年 / 17卷 / 05期

关键词：

familial hypercholesterolaemia; premature coronary artery disease; underdetection;

D O I：

10.1016/j.hlc.2007.06.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Familial hypercholesterolaemia (FH) is a common genetic disorder that untreated has an almost one hundredfold risk of coronary artery disease (CAD). In an audit of 334 patients with premature CAD admitted to a Department of Cardiology, only 60% of medical records had sufficient clinical information for identifying FH. Of those with sufficient information recorded, 54% of patients had possible to definite FH on recognised clinical criteria. Amongst those with FH, only 38%, were on statin therapy and only 22% were treated to National Heart Foundation targets. Detection and treatment of FH represents a major gap in coronary prevention.

引用

页码：411 / 413

页数：3

共 7 条

[1] Familial hypercholesterolaemia is underdiagnosed after AMI [J].

Dorsch, MF ;

Lawrance, RA ;

Durham, NP ;

Hall, AS .

BMJ-BRITISH MEDICAL JOURNAL, 2001, 322 (7278) :111-111

[2]

Hamilton-Craig Ian, 2004, Semin Vasc Med, V4, P87

[3] Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries -: Principal results from EUROASPIRE II Euro Heart Survey Programme [J].

Kotseva, K ;

Wood, D ;

De Backer, G ;

De Bacquer, D ;

Pyöräla, K ;

Keil, U .

EUROPEAN HEART JOURNAL, 2001, 22 (07) :554-572

[4] A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia [J].

Marks, D ;

Thorogood, M ;

Neil, HAW ;

Humphries, SE .

ATHEROSCLEROSIS, 2003, 168 (01) :1-14

[5]

MARKS D, 2002, BRIT MED J, V324, P1

[6] Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study [J].

Neil, HAW ;

Hammond, T ;

Huxley, R ;

Matthews, DR ;

Humphries, SE .

BRITISH MEDICAL JOURNAL, 2000, 321 (7254) :148-148

[7] How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996-1998 versus 1999-2000 [J].

Vale, MJ ;

Jelinek, MV ;

Best, JD .

MEDICAL JOURNAL OF AUSTRALIA, 2002, 176 (05) :211-215

← 1 →